Cellular transformation is enhanced with mutation or overexpression of EGFR as well as erbB2, leading to a poor prognosis in cancer patients, especially those with non-small-cell lung cancer (NSCLC) [4, 5]. Here, EGFR is linked to non-small cell lung carcinoma.